CompletedPhase 1

Using Thermography to Assess the Affects of Sildenafil Cream, 3.6%

Canada13 participantsStarted 2023-05-13

Plain-language summary

The goal of this clinical trial is to compare thermography images in normal healthy premenopausal women after the application of Sildenafil Cream, 3.6%, L-arginine cream, and placebo cream. Participants will be shown a series of explicit videos to elicit a change in genital temperature before and after application of cream.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Exclusion criteria

✕. Dehydroepiandrosterone (DHEA), excluding intravaginal DHEA, testosterone and other androgens, tamoxifen, raloxifene, and other selective estrogen receptor modulators (SERMs)
✕. Any antihypertensive (excluding ACE Inhibitors or Angiotensin II Receptor Blockers), clonidine, alpha blockers or nitrate containing medications.
✕. Beta blockers or other drugs that affect the autonomic nervous system and/or cardiovascular system
✕. Any approved or experimental medications or treatments used to enhance the sexual response (e.g., oral sildenafil, L-arginine)
✕. Any drugs or supplements that may alter amino acid or vitamin status, such as drugs or supplements containing L-arginine or Citrulline.

What they're measuring

Evaluate the difference in vulvar blood flow after the use of investigational products

Timeframe: 14 days

Trial details

NCT IDNCT05765487

SponsorDaré Bioscience, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-01-26

View on ClinicalTrials.gov More Sexual Arousal Disorder trials